Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.
Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection.
Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.
IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation.
Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types.
Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics.
Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy.
Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.